MARKET OVERVIEW- EUROPE CELL FREE PROTEIN EXPRESSION MARKET
Cell-free protein expression (CFPE) is used for producing proteins by using the cell's RNA and protein synthesis machinery in a cell-free system. The components of a CFPE system include a cellular lysate and DNA expressing the protein of interest, along with energy sources, nucleotides, amino acids, salts, and cofactors. It offers the possibility of a rapid prototyping platform for recombinant protein production with the capabilities of post-translational modifications. This method is widely used in enzyme engineering, protein labelling, protein purification, protein-protein interaction, and high throughput mutant production. The growth of the Europe Cell Free Protein Expression Market is driven by the rise in prevalence of cancer and infectious diseases in European nations along with technological advancements in biotechnology sector. Furthermore, the rise in demand for personalized medicines for the treatment of chronic diseases is expected to drive the growth of the market.
MARKET DRIVERS
The growth of the market is driven by the rise in the prevalence of chronic diseases like cancer, diabetes, cardiovascular disease, and others. According to European Cardiovascular Disease Statistics 2017, Each year cardiovascular disease (CVD) causes 3.9 million deaths in Europe and over 1.8 million deaths in the EU. CVD accounts for 45% of all deaths in Europe and 37% of all deaths in the EU. In 2015, more than 85 million people in Europe were living with CVD and almost 49 million people were living with CVD in the EU. In 2015, 1.3 million people died from cancer in the EU, more than one quarter (25.4 %) of the total number of deaths. Europe comprises only one eighth of the total world population but has around one quarter of the global total of cancer cases with some 3.7 million new patients per year. Lung, breast, stomach, liver, colon and breast cancer cause the most cancer deaths annually. Lung cancer accounted for more than one fifth of all cancer-related deaths in the EU in 2015. Thus, the rising cases of chronic disease such as cancer, diabetes, cardiovascular disease, and others create a demand for personalized medicine which can be achieved using cell-free protein expression. This is expected to drive the growth of the Europe cell-free protein expression market over the forecast period. Furthermore, rise in R&D activities in the pharmaceutical industry is expected to positively impact the growth of the market.
MARKET OPPORTUNITIES
Rising investments in R&D activities in genomic research projects are expected to provide ample opportunity for the market. For instance, France Médecine Génomique 2025, sets out proposals for an investment of €670 million over the first five years of the new ‘French Genome Project’, to be accompanied by commercial contributions worth another €230 million. The report sets out a vision for France to ‘consolidate its leading position’ in the field of personalised or precision medicine by establishing a network of centres for rapid, high-throughput genome sequencing and analysis that will be able to handle 235,000 genomes annually by 2020.
MARKET RESTRAINTS
The cell-free protein expression offers low protein production, making it unsuitable for large industrial applications. This, in turn, is likely to hamper the growth of the market. Additionally, the high cost and short reaction scale of cell-free protein expression are expected to restrain the growth of the market.
MARKET GROWTH CHALLENGES
The cost of research activities involved in cell-free protein expression is significantly high. It may negatively impact the growth of the markets. Also, a lack of effective post-translational modification systems in cell-free protein expression is expected to challenge the market growth over the forecast period.
CUMULATIVE GROWTH ANALYSIS
The report provides in-depth analysis of the Europe Cell Free Protein Expression market, market size, and compound annual growth rate (CAGR) for the forecast period of 2023-2029, considering 2022 as the base year. An increase in the prevalence of chronic disease has led to the rise in demand for cell free protein expression technique in various applications, and therefore, the market is expected to witness growth at a specific CAGR from 2023-2029.
EUROPE CELL FREE PROTEIN EXPRESSION MARKET SEGMENTAL OVERVIEW
The Europe Cell Free Protein Expression market includes different market segments like product, application, end users and country.
EUROPE CELL FREE PROTEIN EXPRESSION MARKET BY PRODUCT
By product, the Europe Cell Free Protein Expression market includes the key segments like
- E. coli Cell-free Protein Expression System
- Wheat Germ Cell-free Protein Expression System
- Rabbit Reticulocytes Cell-free Protein Expression System
- Insect Cells Cell-free Protein Expression System
- Human Cell-free Protein Expression System
- Others
The E. coli cell-free protein expression system is expected to dominate the market over the forecast period. E. coli cell-free protein expression systems can synthesize a broad variety of proteins, including soluble proteins such as enzymes or reporters, proteins with disulphide bonds such as antibodies and membrane proteins such as channels or transporter.
The wheat germ cell-free protein expression system is expected to grow at the fastest CAGR. This system offers optimal environment for protein synthesis by allocating all metabolic resources to the protein in question, as opposed to basic cellular mechanisms. It is a key factor driving the growth of the segment.
EUROPE CELL FREE PROTEIN EXPRESSION MARKET BY APPLICATION
The Europe Cell Free Protein Expression market finds key applications in
- Enzyme Engineering
- High Throughput Production
- Protein Labeling
- Protein-Protein Interaction
- Protein Purification
- Other Applications
The enzyme engineering segment is expected to dominate the market over the forecast period. Over the years, cell free protein expression method has become an established tool for rapid protein synthesis in order to accelerate the discovery of new enzymes and the development of proteins with improved characteristics. This is a key factor driving the growth of the segment.
High throughput production is expected to witness high growth over the projected time period. The cell free protein expression method is widely used in high-throughput functional genomics and proteomics, with significant advantages compared to protein expression in live cells. s
EUROPE CELL FREE PROTEIN EXPRESSION MARKET BY END USERS
The Europe Cell Free Protein Expression market includes major end users like
- Hospitals and Clinics
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Others
The pharmaceutical and biotechnology companies are expected to lead the market over the estimated time period. Increasing investments in the biotechnology and pharmaceutical sector in Europe is anticipated to drive the growth of the market.
Furthermore, the academic and research institutes are expected to witness high growth over the forecast period due to the rise in investments in R&D activities in proteomics and genomics.
EUROPE CELL FREE PROTEIN EXPRESSION MARKET BY COUNTRY
The Europe Cell Free Protein Expression market is studied for the following countries
- Germany
- U.K
- France
- Italy
- Spain
- Rest of Europe
Germany is expected to dominate the market over the forecast period. The rise in prevalence of chronic diseases coupled with technological developments in the biotechnological sector are key factors driving the growth of the market in the region. According to the National Center for Health Statistics, in 2019, 502,655 people in Germany were diagnosed with cancer, including 234,925 women and 267,730 men. Thus, rise in prevalence of chronic diseases is expected to drive the growth of the market in Germany.
The U.K is anticipated to witness an increasing demand for the cell free protein expression method owing to rise in R&D activities along with the strategic investments by the government as well as key market players are expected to drive the growth of the market in the U.K. For instance, in December 2022, the U.K government announced a £175 million investment in genomics research, including a study led by Genomics England, in partnership with the National Health Service (NHS), to explore the effectiveness of using whole-genome sequencing to find and treat rare genetic diseases in newborn babies.
COVID-19 IMPACT ANALYSIS ON EUROPE CELL FREE PROTEIN EXPRESSION MARKET
Axiom MRC provides a 360-degree analysis of micro and macro-economic factors on the Europe Cell Free Protein Expression market. In addition, a complete analysis of changes in the Europe Cell Free Protein Expression market expenditure, economic and international policies on supply and demand side is provided in this exclusive report. The report also studies the impact of pandemic on Europe economies, international trade, business investments, GDP, and the marketing strategies of key players present in the market.
The COVID-19 pandemic has significantly affected the health, economy, and society, and has changed the economic situation of the world. The pandemic has affected the most severely vulnerable groups including older people with disabilities, ethnic minorities, and those living in deprived areas. The pandemic had a positive effect on the market. The expression of cell-free proteins has been widely used for the development of various treatments, including COVID-19. This is expected to contribute to the growth of the market in the upcoming years.
COMPETITIVE LANDSCAPE ANALYSIS
The competitive landscape analysis of the Europe Cell Free Protein Expression market is primarily focused on expanding the growth of the cell free protein expression industry in Europe region with new product innovation, business expansion, increasing presence of a range of manufacturers operating in cell free protein expression sector has led to growing demand for the market. Besides, the market offers a range of products in different applications to fulfil the required demand of consumer which further contributes healthy growth in the market.
The key players studied in market are
- Merck KGaA
- Cube Biotech GmbH
- CellFree Sciences Co., Ltd.
- Promega Corporation
- Thermo Fisher Scientific
- Creative Biolabs
- Bioneer Corporation
- Jena Bioscience GmbH
- New England Biolabs
- Biotechrabbit GmbH
- LenioBio GmbH
- Moderna Therapeutics
- GeneCopoeia, Inc
- Takara Bio
- Sutro Biopharma Inc
- Otsuka Holding Co. Ltd.
RECENT DEVELOPMENT:
January 2022: Merck KGaA had announced that it has acquired Exelead, a biopharmaceutical contract development and manufacturing organization (CDMO), for approximately USD 780 million.
February 2020: Max Planck researchers from the Institute of Biochemistry, Germany, summarized the development of an in vitro translation system that enables self-encoded replication and expression of large DNA genomes under well-defined, cell-free conditions.
